目的:本文主要探讨HPV E6/E7 mRNA与薄层液基细胞学检测(Thinprep Cytologic Test, TCT)结合在子宫颈癌及癌前病变筛查中的价值。方法:选取2018年1月~2022年12月期间在延安市人民医院就诊的均进行过HPV E6/E7 mRNA、TCT的宫颈异常患者674例,以活检组织病理结果为金标准,分析不同检查方法对宫颈癌及癌前病变的筛查价值。结果:674例活检阳性的病例中:HPV E6/E7 mPNA检出阳性448例,TCT检出阳性371例;HPV E6/E7、TCT检查的诊断一致性为63.35%;与联合检测比较,HPV E6/E7 mRNA、TCT在宫颈癌前病变的检测中符合率均较低,差异均有统计学意义(P Objective: To analyze clinical application value of HPV E6/E7 mRNA and Thinprep cytologic test (TCT) detection in screening for cervical lesions. Methods: A total of 674 patients with cervical abnormalities who underwent HPV E6/E7 mRNA and TCT in Yan’an people’s Hospital from January 2018 to December 2022 were selected. With the histopathological results as the gold standard, the screening value of different examination methods for cervical cancer was analyzed. Results: Histopathological biopsies showed that the diagnostic concordance of HPV E6/E7 and TCT was 62.42%, and the sensitivity, specificity and accuracy of HPV E6/E7, TCT and colposcopy in detecting HSIL + SCC were all lower compared with the combined test, and the differences were statistically significant (P < 0.05). Conclusion The combination of HPV E6/E7 mPNA and TCT improve the value of screening for cervical cancer and may help in better clinical diagnosis and treatment.
